Harvard Bioscience
HBIO
HBIO
100 hedge funds and large institutions have $90.7M invested in Harvard Bioscience in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 42 increasing their positions, 25 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
1.66% less ownership
Funds ownership: 74.9% → 73.24% (-1.7%)
34% less capital invested
Capital invested by funds: $138M → $90.7M (-$47.2M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
100
Holding in Top 10
1
Calls
$32K
Puts
$17K
Top Buyers
1 | +$1.21M | |
2 | +$886K | |
3 | +$591K | |
4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$428K |
5 |
Millennium Management
New York
|
+$369K |
Top Sellers
1 | -$3.7M | |
2 | -$1.95M | |
3 | -$1.11M | |
4 |
![]()
New York State Common Retirement Fund
Albany,
New York
|
-$460K |
5 |
AE
AMH Equity
Great Neck,
New York
|
-$354K |